Tags : China

Bayer and 111 Collaborate to Explore the Vast Blue Ocean

Shots: The companies will collaborate on drug commercialization initiatives in China, including the commercialization of innovative drugs & healthcare products for chronic disease management, as well as providing reliable and convenient resources for patient education Bayer will leverage 111’s vast network of pharmacies and healthcare providers to enhance its channel management and patient outreach capabilities, […]Read More

Bayer Reports the NDA Submission to NMPA for Vericiguat to

Shots: The NDA submission was submitted to NMPA’s CDE and is based on P-III VICTORIA study, seeking regulatory approval of vericiguat in China In Oct’2014, Bayer and MSD signed a WW agreement for sGC modulators. The therapy is being jointly developed by both the companies as per the collaboration and has received the US FDA’s […]Read More

BeiGene Signs a License and Supply Agreement with Bio-Thera for

Shots: Bio-Thera to receive $165M upfront, regulatory, and commercial milestones and is eligible to receive royalties on sales of the product. BeiGene to get the right to develop, manufacture, and commercialize BAT1706 in China, including Hong Kong, Macau, and Taiwan while Bio-Thera will retain rights for the therapy outside the licensed territory The NMPA has […]Read More

Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297)

Shots: The two companies will co-develop and conduct clinical trials for senaparib across multiple cancer indications in China. Junshi to invest $43.4M in cash, representing 50% of the JV while Impact will supply senaparib in Mainland China, Hong Kong, and Macau representing the other 50% The JV will focus on the research, development & commercialization […]Read More

Henlius’ HLX02 Receives the NMPA’s Approval as the First Trastuzumab

Shots: On Aug 14, 2020, HLX02 (biosimilar, trastuzumab) received NMPA’s approval to treat HER2+ early BC, HER2+ m-BC and HER2+ m-gastric cancer. Additionally, On 27th July, HLX02 has received EC’s approval under the brand name Zercepac Henlius followed the NMPA and EMA’s biosimilar guidelines and has taken multiple head-to-head comparisons b/w HLX02 and the reference, […]Read More

Eli Lilly Amends its 2013 Agreement with Chi-Med to Commercialize

Shots: Chi-Med to receive 70%-80% of Elunate sales in the form of royalties, manufacturing costs and service payments with no upfront regarding this amendment. Lilly will maintain the exclusive commercialization rights and will continue to consolidate the sales of Elunate in China while Chi-Med retains all rights to fruquintinib outside of China The agreement allows […]Read More

Innovent Receives the NMPA’s Approval for Byvasda (biosimilar, bevacizumab) to

Shots: The NMPA has approved Byvasda for the treatment of patients with NSCLC and metastatic colorectal cancer. The approval follows TYVYT (sintilimab injection) approval, indicated to treat patients with Hodgkin’s lymphoma, granted in Dec’2018 The launch of Byvasda will provide Chinese patients with high-quality and relatively more affordable bevacizumab biosimilar injection In Jan’2020, Innovent granted […]Read More

Boehringer Ingelheim Receives Approval for its Classical Swine Fever Live

Shots: Boehringer’s Ingelvac CSF MLV has obtained a New Veterinary Drug Registration Certificate from the Ministry of Agriculture and Rural Affairs of China The vaccine is jointly developed by Boehringer and Chinese research institutes and will be produced at BI’s Taizhou plant, Jiangsu province, and is expected to be commercialized in H1’21 The vaccine is […]Read More